Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on August 26, 2008
JNCI Journal of the National Cancer Institute 2008 100(17):1202-1203; doi:10.1093/jnci/djn316
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/17/1202    most recent
djn316v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Major Treatment Improvements Encourage Kidney Cancer Researchers To Seek Further Gains

Rabiya S. Tuma

The first 150 words of the full text of this article appear below.

Targeted therapies have improved clinical outcomes over the past several years for patients with advanced renal cell cancer. Data presented at this year's annual meeting of the American Society for Clinical Oncology (ASCO) showed that overall survival for previously untreated patients has increased from just over 1 year to more than 2, and patients who relapsed while being treated with antiangiogenesis therapies can benefit from treatment with a different targeted drug.

Researchers are cautiously optimistic that combinations of existing therapies will allow the trend to continue, though early trial data suggest that another substantial improvement will be hard to find with existing molecular targets and drugs. Some researchers, however, contend that extending median survival is no longer an adequate goal and that the field really should be pushing for curative therapy.

"This field had basically nothing—cytokines—for years and years, and with targeted therapy it has taken a quantum leap," said . . . [Full Text of this Article]

First- and Second-line Therapies

Combining Agents

Pushing for the Next Advance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?